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PREDICTING DISENGAGEMENT FROM CARE IN AN EARLY PSYCHOSIS 
PATIENT COHORT IN THE UNITED STATES. 
Matthew Kruse, Vivek Phutane, and Vinod Srihari. Department of Psychiatry, Yale 
University, School of Medicine, New Haven, CT. 
The current study aims to assess baseline variables which may predict disengagement 
from care among patients with psychosis seeking treatment at an early intervention clinic 
in the United States. Based on literature published at sites outside the United States, we 
predict that duration of untreated psychosis, global assessment of functioning, forensic 
history, family contact, and substance abuse are predictive of disengagement during the 
first year of outpatient treatment. Patients were grouped according to whether or not they 
disengaged from care in a one year follow-up, and compared them on the above discrete 
and continuous variables with chi-square analysis and Student‟s t-tests, respectively. 
Although none of the statistical tests reached significance, data trends suggest that longer 
duration of untreated psychosis, lower global assessment of functioning, forensic history, 
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Psychotic Illness and Treatment Challenges 
Schizophrenia and other psychotic disorders are a series of related, typically chronic 
conditions that respond best to stable, long-term treatment (1). The lifetime prevalence of 
any psychotic disorder is estimated to be approximately three to four percent (2), are 
costly to treat, and even with widespread use of antipsychotic pharmacotherapy, continue 
to be a major source of lifetime disability (3, 4). The exact reasons some individuals 
develop psychosis are still incompletely understood. Etiologically, prominent theories of 
schizophrenia and related psychotic illnesses include abnormal neurodevelopmental 
models (supported by evidence that patients may have structural brain abnormalities such 
as ventricular enlargement prior to onset of illness), neurodegenerative models (supported 
by evidence that stable schizophrenic patients who relapse following removal of 
antipsychotic medication often are unable to return to prior levels of wellness), and 
neurochemical models, with particular suspicion of dopaminergic and glutamatergic 
imbalance (5). Indeed, there are many forms of psychotic disorders with varied 
constellations of positive (such as hallucinations or disorganized thought) and negative 
symptoms (such as flattened affect or catatonia), likely representing a spectrum of 
neurobiologically distinct disorders (6). Accordingly, studies have identified a variety of 
risk factors associated with psychotic illness, including substance abuse (7), family 
history (8, 9), prenatal insults (10), and even geographic setting or culture (11, 12). 
Nevertheless, many authors agree that most forms of psychosis are the result of a 
complex interaction of genetics and environment (7, 11, 13).  
5 
 
Apart from the cognitive and functional disabilities inherent to psychosis, literature has 
suggested that patients with a psychotic illness are at higher risk for somatic 
complications such as obesity, diabetes, and cardiovascular disease (14). These chronic 
medical conditions may help explain data showing that the life expectancy of individuals 
with schizophrenia or other psychotic disorders may be reduced by 15 to 25 years (14-
16). There is evidence that the morbidity and mortality associated with psychotic 
illnesses may be intrinsically related to the biological processes underlying psychosis. A 
review on predisposition for metabolic syndrome and cardiovascular risk in 
schizophrenia suggests that present data is conflicting, but drug-naïve patients with 
schizophrenia may have greater baseline levels of insulin sensitivity and higher blood 
glucose levels than controls (17). In addition, rates of suicide and attempted suicide are 
particularly high among patients with psychosis, with a lifetime risk of five percent (18).  
Nevertheless, the impact of environmental influences cannot be ignored. First, some 
types of unhealthy lifestyle choices tend to occur at higher rates in these patients. A 
review of the literature notes that rates of smoking in patients with schizophrenia may be 
as high as 85% (much higher than the estimated 23% in the general population of the 
United States), and up to 40% of patients with schizophrenia may be smoking more than 
30 cigarettes daily. Secondly, the morbidity and mortality associated with psychosis may 
be exacerbated by the metabolic and other systemic side effects that commonly occur 
with some antipsychotic medications (14, 19). Aside from the risks of medical 
disabilities, logistical and financial obstacles may be significant barriers to psychiatric 
care for patients with psychosis. A survey of patients with serious mental illness in the 
United States revealed that among those who did not seek desired psychiatric care, 46% 
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cited lack of insurance coverage or prohibitive out of pocket expenses, and 52% had 
situational problems, including uncertainty of where to seek help or time constraints (20). 
Among a cohort of first-episode of psychosis (FEP) patients in New Haven, Connecticut, 
33% of patients were uninsured at baseline, and among those who were insured, only 
29% maintained coverage over the first year of psychiatric treatment. Even among those 
who were eligible for public insurance, 38% lost coverage over this period (21). Taken 
together, despite the development of multiple generations of antipsychotic medications, 
there remains significant room for improvement in the clinical and psychosocial 
interventions for patients with psychotic disorders. 
Engagement and Disengagement 
The previous section outlined the treatment challenges that accompany psychotic 
disorders, and began to address the various barriers to care facing many patients suffering 
from them. Unfortunately, merely connecting patients with care is inadequate, and 
authors agree that maintaining treatment and preventing service disengagement is critical 
for producing good clinical outcomes while preventing morbidity, mortality, and 
psychosocial decline (18, 22). Before service disengagement can be discussed further, the 
definition of term „disengagement‟ should be examined. 
Strikingly, despite a rather voluminous body of literature on the topic of disengagement 
from psychiatric services, there is no consensus on what constitutes “disengagement.” 
For instance, Fischer et al. define disengagement among a cohort of patients with 
schizophrenia or bipolar disorder as “a period during which a cohort member had no 
documented contact” with his or her mental or medical healthcare providers (23). This 
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study identified all disengagement periods greater than three months, but focused most of 
their analysis on disengagement periods of 12 months or greater. Kessler et al. defined 
disengagement among patients with serious mental illness as having sought psychiatric 
care at any time in the preceding 12 months, but not currently seeking treatment for any 
reason other than an improvement in symptoms (20). Olfson, meanwhile, simply defines 
disengagement as the discontinuation of treatment earlier than intended by a clinician 
(24). In an assessment of psychiatric service use of first-time patients in South Verona, 
Italy, Tansella provides a more formal definition of disengagement. Service use was 
described in terms of „episodes of care‟ and „break values‟ (25). A „break value‟ is 
considered the amount of time that must pass between clinical contact before a patient 
can be considered disengaged from active treatment. An „episode of care‟, meanwhile, is 
the time that passes before a patient hits a given „break value.‟ They calculate patterns of 
service use using break periods ranging from seven days to 183 days. As would be 
expected, when a seven day break value was used, the median episode of care in their 
sample was one day. They reason that only the most acutely ill patients are seen in 
outpatient clinic more than once every seven days. Therefore, a seven day break value is 
too sensitive, producing excessive disengagement false-positives. After recalculating 
using various break values, they found that 90 days appeared to be the optimally sensitive 
and specific break value. The authors note that a 90 day break value is consistent with the 
clinical needs of patients, and had used this value in prior publications (25). 
Nevertheless, literature reviews have suggested that in general, psychiatric patients in the 
United States have a disengagement rate of about 20% (24). Among patients with 
psychosis, a systematic review uncovered estimates of disengagement rates ranging from 
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24 to 90%. The average rate of disengagement among the 86 studies analyzed, weighted 
for sample size, produced an estimate of 26% disengagement rate. The definition of 
disengagement in this review cannot be defined, as rates of disengagement were assessed 
according to the definition used in each study included in the meta-analysis. (26)  
Predicting Disengagement 
Even if there is ongoing disagreement in the literature on what constitutes 
disengagement, and what the true rate of disengagement is among various patient 
populations, there have been factors associated with greater risk for disengagement from 
care both in cases of psychotic illness as well as in general psychiatric populations. 
Namely, younger age (24, 27), living apart from family (28, 29), lack of insurance (30), 
forensic history (29, 31), less use of available services (27), longer duration of untreated 
psychosis (DUP) (32), lower baseline global assessment of functioning (GAF) (28), lack 
of insight (33), and persistent substance abuse (24, 28, 29) often correlate with higher 
rates of service disengagement.  
In addition to these factors, early stage of treatment is a particularly critical time for 
preventing disengagement from care. Data has shown that first-time psychiatric patients 
are almost six times more likely to drop out of treatment if they have had fewer than three 
clinical visits, with authors hypothesizing that once rapport and trust is established over 
time, risk of disengagement decreases (24). Among patients with psychotic illnesses, side 
effects of antipsychotic medication, which may occur early in treatment, could be 
contributing the high rates of disengagement early in treatment. One study demonstrated 
that a 12 week course of some antipsychotics in treatment naive adolescents produced 
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significant weight gain and triglyceride elevation that was not observed in unmedicated 
controls (34). These side effects may provide incentives for patients to disengage from 
care and discontinue medication during the first few weeks of treatment if a strong 
therapeutic relationship has yet to be established. The Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) study indeed demonstrated that among an array of 
first- and second-generation antipsychotics, 74% of patients discontinued their 
antipsychotic medication within 18 months, often due to side effects or perceived lack of 
efficacy (19). 
Duration of Untreated Psychosis 
Of the factors listed above, much emphasis has been placed in the literature on DUP, 
defined as the lapse in time between the onset of psychosis and the start of treatment. 
DUP receives emphasis not only as a predictor of disengagement, and poor clinical 
outcomes, but also as a valuable tool for examining the natural progression of psychotic 
illness (35-37). An examination of DUP in patients living in Nova Scotia, Canada 
showed that longer DUP is associated with more severe negative symptoms and social 
withdrawal at baseline, in addition to more severe positive symptoms and lower GAF 
scores six months into treatment (35). Similarly, Schimmelmann et al. demonstrated that 
longer DUP is associated with worse illness severity, positive symptom remission rate, 
and general functioning after 18 months of treatment (37). A meta-analysis of 26 studies 
demonstrated that DUP correlated significantly with worse depression, anxiety, positive 
and negative symptoms, social functioning, and overall quality of life 12 months into 
treatment (32).  
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Conversely, a study of first-episode schizophrenia patients in West London found only 
older age to be significantly associated with DUP longer than 26 weeks. They found 
some data trends linking longer DUP and more errors on a computerized neurocognitive 
task, as well as longer duration of untreated illness (but not DUP) with poorer initial 
response to antipsychotics. (Duration of untreated illness was defined as DUP plus the 
length of any prodromal symptoms.) Though the sample size was limited (n = 53), the 
authors were nevertheless skeptical that untreated psychosis may be conferring any 
inherent challenges to treatment once a connection to care is established. Instead, they 
hypothesize that longer DUP may be linked to confounding variables such as social 
isolation or less socially-conspicuous negative symptomology which may prolong the 
time to seeking treatment (38). Polari et al. stress that poor adherence to medication while 
attending medical appointments might be considered part of the DUP period, potentially 
accounting for some of the variation in findings on the effect of DUP in studies that 
might not necessarily be measuring this metric (36). 
First-Episode Psychosis and Early Intervention 
The potential importance and benefits of limiting DUP, combined with the insight that 
several predictors of disengagement, including younger age and early treatment phase, 
tend to co-segregate in patients with first-episode psychosis (FEP), has rendered this 
population of particular importance to investigators interested in optimizing outcomes in 
patients with psychotic illness. A survey in the U.K. of patients with FEP found that the 
67% were between 16 and 30 years old, 86% were unemployed, and 72% had 
discontinued education by the age 16 (39). Sixty-two percent of a FEP cohort in Australia 
was found to have a substance use disorder at baseline assessment (40). These 
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demographic and socioeconomic trends in FEP underscore concerns that intervention 
should be initiated as early as possible to prevent the medical, psychiatric, and 
psychosocial decline that is common in this population by the time care is initiated (14, 
41).  
Aside from establishing care, the particularly high risk of disengagement within the first 
two appointments of care following discharge from an emergency department or inpatient 
psychiatric unit has prompted investigators to stress that it is critical to establish a strong 
clinical relationship as early as possible (24). This insight, combined with the challenges 
in treating FEP discussed, has inspired a growing number of specialized early 
intervention clinics aimed at initiating treatment as early as possible in the course of any 
psychotic illness, either in the prodromal phase (prior to the onset of frank psychosis) or 
as soon as possible after the onset of psychosis, effectively reducing DUP (42).   
One of the flagship programs studying the effects of specialized early intervention in FEP 
was the Buckingham study, established in 1984. The program was established in rural 
England to improve the recognition and prompt treatment of patients in the earliest stages 
of serious mental illness, employing several key strategies. Initial psychiatric evaluations 
were performed at a location convenient to the patient. Primary care providers were given 
additional training and screening tools to improve their detection of serious mental illness 
during routine checkups. Specialized psychiatric consultations were made readily 
available, often performed collaboratively with a patient‟s primary care provider (43).  
Once patients were identified as potentially in the early stages of schizophrenia, 
specialized treatment interventions were immediately implemented. First, patients were 
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educated on all parameters of their illness, with an emphasis on the good prognosis that 
may be achieved with stable, long-term treatments. Second, sources of a patient‟s 
stressors were identified, especially in cases where precipitating life events were 
suspected to have triggered psychiatric symptoms, and stress management was instituted 
with an intensity appropriate to a particular patient‟s needs. Finally, these psychosocial 
interventions were complemented by low-dose antipsychotic medication, targeted at the 
correction of a particular deficit, such as insomnia or thought disturbances, and 
discontinued when the target symptom had resolved. Once prodromal symptoms had 
resolved, primary care providers took responsibility for close, long-term monitoring for 
any signs of relapse (43). 
Many of the key features of the Buckingham study have been implemented in later early 
intervention programs, including lower-dose antipsychotics, comprehensive case 
management, supportive psychotherapy, psychoeducation for patients and families, and 
group cognitive-behavioral therapy (41, 44-46). 
The rationale behind the continued and growing support for specialized early intervention 
clinics for FEP is multifaceted. First, early specialized intervention may help prevent 
functional decline and improve clinical outcomes, applying a preventive philosophy to 
psychosis treatment. By asserting more intensive outpatient follow-up early in the course 
of illness, the degenerative neurobiological changes that have been hypothesized to 
accompany untreated psychosis may be avoided (5). In addition, patients with FEP often 
report adverse events in the time leading up to their first connection with psychiatric care. 
One survey revealed that significant functional disability develops over the course of 
untreated psychosis, and 14% of FEP patients in Melbourne attempted suicide prior to 
13 
 
treatment (41). A review by Goff et al. also points out that rates of infectious disease, 
including influenza, HIV, and hepatitis C is particularly high among individuals with 
serious mental illness, due in large part to unhealthy lifestyle habits that occur with 
higher frequency in this patient population. Findings such as these provide a compelling 
argument for earlier, more assertive intervention driven by the ideals of preventive care 
(14). A comparison of early specialized versus standard treatment for FEP patients in 
Denmark suggests that the specialized approach produced superior positive and negative 
symptom relief at one and two years into treatment. In addition, the group receiving 
specialized treatment demonstrated lower rates of substance abuse, and greater service 
engagement (46). A similar study of 144 first- and second-episode psychosis patients by 
the Lambeth Early Onset team in the U.K. failed to find a significant advantage for 
specialized treatment in symptom reduction at 18 months, but did report that specialized 
treatment produced superior measures of quality of life and global functioning at 18 
months (47). Psychiatric patients with access to dual modality treatment, including both 
pharmacotherapy and talk therapy, have been shown to be less likely to dropout from 
care (30). In addition, Iyer et al. demonstrated that aside from symptom relief, patients 
with FEP in Chennai, India most frequently cited vocational, educational, and 
interpersonal improvement as their highest priority goals for treatment. By emphasizing 
these global issues in treatment through modalities including vocational rehabilitation and 
family education, early intervention clinics may be aligning themselves more closely with 
a patient‟s personal goals, helping build strong therapeutic alliances more efficiently (45). 
This may help explain an analysis of an early intervention clinic in the U.K. which 
revealed lower dropout rates than standard treatment controls (44).  
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Economically, early intervention may yield additional benefit, especially in terms of cost-
effectiveness of treatment, more optimal allocation of scarce resources, and improved 
educational and vocational outcomes. As mentioned previously, early intervention clinics 
aim to provide more intensive outpatient care with an emphasis on crisis prevention. An 
analysis of patients with psychosis in the U.K. demonstrated that while 86% of FEP 
patients were unemployed at initiation of treatment, unemployment reached 100% in 
patients with a second episode of psychosis (39). If patients are identified and treated 
earlier, the psychosocial decline associated with more severe cases of psychosis may 
theoretically be prevented, reducing rates of unemployment. 
A cost-effectiveness analysis was performed at an early intervention for psychosis clinic 
in Milan, Italy. In both groups, treatment was administered for approximately five years, 
and both groups demonstrated significant clinical improvement, as measured by the 
Health of Nation Outcome Scales (HoNOS), an inventory measuring a variety of clinical 
and social outcomes relevant to psychotic illness. The average daily costs of treatment in 
the early intervention group and the standard care group were similar (€22.60 and €23.00 
per patient, respectively), but the specialized treatment group demonstrated a larger 
absolute decrease in the HoNOS measure of illness severity. The authors concluded that 
specialized treatment is cheaper per unit of improvement in symptoms and global 
functioning (€4802 versus €9871 per unit reduction in severity on the HoNOS) . They 
additionally noted that more expensive outpatient interventions such as psychotherapy 
rendered specialized treatment more expensive in the first two years of treatment, but 
became less expensive than standard treatment in the last three years, likely due to a trend 
in fewer admissions to and shorter stays in inpatient care facilities (though this data trend 
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fell short of statistical significance). Standard care, meanwhile, became linearly more 
expensive, on average, over the five year course of treatment, again, potentially due to 
greater use of inpatient psychiatric services among this patient group (48). Indeed, 
analyses of early intervention clinics in Melbourne, Australia (49) and the U.K. (44) 
demonstrated statistically significant reductions in hospitalization rate compared to 
standard treatment controls.  
It may be too soon to draw definitive conclusions on the benefits of early intervention 
clinics. A recent Cochrane Review article found that specialized early intervention for 
FEP did improve compliance with treatment, but failed to find statistically significant 
benefits on other outcome metrics, including hospitalization, relapse, and suicide. The 
authors, however, noted the limited number of studies from which to draw conclusions, 
and underscored the importance for more, higher-powered studies to more fully elucidate 
potential benefits of early intervention, and whether these benefits are maintained over 
time (50).  
Criticism of Early Intervention 
Despite the urging for more data and the efforts on the parts of investigators, the 
movement towards earlier intervention for psychosis is not without its critics. Pelosi et al. 
argue that intervention earlier in the course of illness – particularly during the prodromal 
phase of psychosis – will lead to a greater number of patients being inappropriately 
treated for a psychosis who would never have developed the illness, noting that 
symptoms of a prodromal psychotic illness are far more common than psychotic illnesses 
themselves. Aside from the risks of treating patients prior to full onset of psychosis, he 
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additionally notes that some patients with psychosis will improve spontaneously without 
treatment, with earlier interventions at greater risk of providing unnecessary treatment to 
these patients (51, 52). 
Pelosi additionally notes that the growing number of early intervention clinics may be 
diverting the limited resources of the already strained mental healthcare infrastructure 
away from the majority of patients with a long history of psychotic illness to better fit the 
needs of a select few early in the course of illness. Furthermore, he suggests that by 
discharging patients to standard care following a finite course of treatment during more 
critical periods of intervention (often the first few years following onset of psychosis), 
early intervention clinics are providing the very same fragmented care that they were 
designed to avoid (51, 52). Finally, some in the psychiatric community question whether 
the selection criteria of many early intervention clinics, such as limited duration of 
psychotic illness and little-to-no prior courses of antipsychotic medication, may be 
introducing a selection bias for patients with better prognoses or who may have 
spontaneously improved without intervention. Aside from providing inappropriate 
treatment, such recruitment practices may in fact be skewing data towards better 
outcomes, obscuring the true benefit of specialized early intervention (53). The concerns 
regarding early intervention are certainly valid. Even as the behavioral and neurologic 
antecedents to schizophrenia and other psychotic illnesses become more refined, there 
remains a considerable challenge in predicting future cases of psychotic illnesses with 
much specificity. Some authors note, however, that this lack of specificity may actually 
potentiate the benefit of early intervention through prevention of behaviorally or 
biologically related conditions such as bipolar disorder, as long as the dangers of 
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treatment are minimized (54). As long as antipsychotic medication remains a treatment 
mainstay, however, side effects of intervention will continue to be a legitimate concern. 
In a review of the literature on metabolic side effects of antipsychotic medication in FEP 
patients, Foley and Morley found that significant increases in weight, insulin resistance, 
cholesterol, and fasting glucose could be present within six to eight weeks (55). On the 
other hand, the multiple modality treatments for psychosis characteristic of early 
intervention, with a use of lower-dose antipsychotic medication, may reduce the risks of 
extra-pyramidal symptoms or metabolic side effects of treatment (56). In a review on the 
use of antipsychotic medication in FEP, Francey et al. even suggest that psychosocial 
interventions alone may be sufficient in the treatment of some cases of early psychosis, evading 
their cardiovascular risks completely (57). Furthermore, Conus et al. note that FEP patients 
have typically experienced significant social and psychiatric decline prior to engagement 
with an early intervention clinic. As a result, they suggest treatment during the prodrome 
of psychosis may be necessary to truly optimize outcomes, and treating only after the 
onset of a full psychosis, as critics of early intervention recommend, may be too late (41). 
Concerns regarding the fragmented care of patients discharged from specialized treatment 
to standard care following the critical period of illness has been examined by several 
studies. A two year early intervention (OPUS trial) in Denmark found that the clinical 
benefits of specialized treatment at two years were no longer present in at a five year 
follow-up (58). A clinic in Canada, however, provides specialized FEP care for five 
years, though with much lower intensity after the second year of treatment, and found 
persistent improvement in symptoms at a five year follow-up, lending support for the 
need of longer continuity of care in early intervention clinics (59).  In a separate follow-
up assessment of Canadian FEP patients discharged to standard care following three 
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years of specialized intervention, Addington and Addington find that patients maintained 
benefits on metrics of positive symptoms, and continued improvement in negative 
symptomology and quality of life scales over a four- to five-year follow-up period. 
(Although, only approximately half of patients could be followed up following discharge, 
potentially biasing results towards patients who retained higher functioning.) (60)  
Even though the rationale and promise of early intervention clinics has its critics, a 
growing number of elements of specialized early intervention are becoming validated by 
experts. The Schizophrenia Patient Outcomes Research Team (PORT) treatment 
recommendations is a review published periodically which analyzes the current literature 
to assess which psychosocial interventions for schizophrenia are supported by evidence, 
and makes recommendations for standard treatments. In the 2009 update of PORT, they 
recommend the use of Assertive Community Treatment involving a multidisciplinary 
treatment team and higher frequency of contact between patients and clinicians. Also 
recommended is a broader treatment focus, emphasizing vocational and interpersonal 
skills, access to cognitive behavioral therapy, and family education. At the time of 
writing the 2009 PORT recommendations, there was insufficient evidence for the authors 
to officially endorse psychosocial treatments for recent onset schizophrenia. They 
nevertheless express optimism for this intervention, noting the early intervention data is 
“witnessing substantial progress,” and note that their inability to officially endorse early 
intervention was “primarily due to small numbers of studies for any given intervention 




Early Intervention in the United States 
Helping to answer the call for more data regarding early intervention for psychosis, the 
Specialized Treatment Early in Psychosis (STEP) program at the Connecticut Mental 
Health Center in New Haven, CT, is an NIH-funded pilot program that aims to 
investigate the effects of multidisciplinary, evidence-based intensive outpatient 
intervention in the United States. Briefly, its focus is to replicate and further elucidate the 
benefit of early intervention in psychosis in a cohort of FEP patients in the United States 
using a pragmatic randomized controlled trial paradigm (described in detail in the 
following methods section). 
STEP is one of the first specialized early intervention in psychosis clinics in the United 
States (61). As noted previously, the benefit of the psychiatric interventions assessed by 
early intervention clinics may vary between geographic regions due to variances in 
standard care protocols, making extrapolation of currently available data to the United 
States unreliable and necessitating replication studies (62). 
Statement of Purpose 
The current study aims to explore data on disengagement from an early intervention 
psychosis clinic in the northeast United States. Our first aim is to begin elucidating the 
effects of early intervention in the United States, where there is currently little published 
data, focusing on predictors of disengagement in an FEP cohort. The fragmented care that 
is typically available to patients in the US, particularly in psychiatric populations, renders 
engagement in a strong, long-lasting connection to a mental healthcare facility of 
particular importance (62, 63). We will explore whether previously identified predictors 
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of disengagement can be replicated in our patient sample. Specifically, we hypothesize 
that younger age, longer DUP, lower baseline GAF, forensic history, less family contact, 
and substance abuse will associate with higher rates of service disengagement. In 
addition, as many studies on disengagement from service seem to rely on varied or even 
vague definitions of disengagement (64), we hope to contribute data centered on a 
clinically reasoned, objectively measurable definition of disengagement. 
Method 
Setting 
The current study was conducted at Connecticut Mental Health Center (CMHC), a 
publicly-owned mental health treatment facility that operates as part of the Connecticut 
Department of Mental Health and Addiction Services (DMHAS). CMHC and much of its 
clinical staff are additionally affiliated with the Yale University School of Medicine. 
CMHC provides inpatient and outpatient mental health care to uninsured or publicly 
insured-patients over the age of 18 living in New Haven, CT and surrounding 
communities, representing a catchment of approximately 200,000 eligible individuals 
(61).  
Clinical data was obtained from the Specialized Treatment Early in Psychosis (STEP) at 
CMHC, an NIH-funded pilot program designed to investigate the clinical and economic 
benefit of evidence-based interventions early in the course of psychosis. STEP was 
designed as a pragmatic randomized controlled trial that enrolled all patients early in the 
course of a psychotic illness (61). To be eligible for enrollment in STEP, patients have be 
over 18 years of age, currently suffering from first episode of psychosis (FEP), and have 
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fewer than eight weeks of lifetime treatment with an antipsychotic medication. Patients 
need not be eligible for public-sector care, and those with co-morbid psychiatric illnesses 
are eligible as long as there is no developmental or intellectual disability present. Once 
enrolled in STEP, patients are assigned to either STEP treatment at CMHC or 
randomized out to a control “treatment as usual” (TAU) group, receiving care at either 
CMHC or with a private mental health practitioner. Patients enrolled to receive care from 
STEP do so free of charge. The length of treatment is determined individually by each 
patient‟s symptom profile, response to treatment, and clinical needs. 
The majority of patients enrolled in the STEP study are recruited either by referral from 
Yale Psychiatric Hospital following admission or from regional hospitals. 
STEP employs several treatment strategies for early psychosis patients. Aside from 
standard antipsychotic pharmacotherapy, patients also have access to group cognitive-
behavioral therapy. Individual case managers assist patients with the educational and 
vocational difficulties that are common among patients with psychotic illnesses. In 
addition, assertive interventions, including frequent clinical contact with a primary 
clinician (typically a social worker or psychiatric nurse) as well as phone and written 
appointment reminders to patients, aim to decrease clinical drop-out from care. After 
enrollment in the STEP study, outcome data is gathered on each patient at baseline and 6 
month intervals (61). Data collected is described in more detail in a later section. 
Patients 
The current study examines patients enrolled in the experimental arm of STEP treatment. 
In accordance with STEP‟s research protocol, all patients were between ages 18 and 45 at 
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time of enrollment in STEP, suffering from a first episode of a psychotic illness. 
Appropriate diagnosis for inclusion in STEP was determined by guidelines published in 
the DSM-IV-TR (6), as assessed by clinical evaluation and the Structured Clinical 
Interview for DSM-IV (SCID) and chart review by a psychiatrist or psychologist on staff 
at STEP. Exclusion criteria include evidence for substance-induced psychosis, prior 
episodes of diagnosed psychosis, or prior antipsychotic pharmacotherapy of greater than 
eight weeks (61). All patients were retrospectively evaluated over a period of one year 
following enrollment in STEP. Patients enrolled for less than one year at the time of 
analysis, or for whom complete clinical records were not available, were excluded. 
Assessment of Service Disengagement 
Patients were classified as having either remained engaged or disengaged over the first 
year of STEP treatment. Disengagement was defined as having been out of contact with 
all STEP service providers for a period of 3 months or greater during their first year of 
outpatient follow-up, even if they did eventually return to care. Clinical contact was 
assessed by chart review. Attendance to appointments was confirmed by clinic notes, and 
non-attendance was confirmed by lapses in progress notes and records indicating missed 
appointments. Engagement was tracked with a one month resolution. In cases of service 
disengagement, the month of the last appointment attended was considered the month 
when disengagement occurred. 
The one year follow-up period and current definition of disengagement were chosen for 
several reasons. First, as noted, literature suggests that the earliest stages of clinical care 
following a first episode of psychosis may be the most critical period for establishment of 
23 
 
a strong therapeutic relationship and optimizing clinical and functional outcomes (24), so 
the decision was made to focus on the first year of treatment. From a treatment 
standpoint, a period of no clinical contact of three months or greater within the first year 
of care following FEP would not be consistent with the assertive treatment modality 
employed by STEP, and we considered a three month absence a reasonable indicator of a 
patient‟s failure to attend scheduled appointments. Our three month definition of 
disengagement is additionally supported by the above-mentioned analysis by Tansella, et 
al. which suggests a shorter period may be too sensitive, inappropriately labeling active 
patients as disengaged, and longer periods may inappropriately label patients who only 
sporadically attend appointments, as fully engaged (25).  In addition, the primary 
importance for investigating predictors of and reducing rates of disengagement is to 
improve outcomes by effecting greater continuity of care (64). Therefore, we consider 
any instances of disengagement an indicator that a patient is not receiving optimal 
continuity of care, and have classified patients as disengaged even if they eventually 
return to care during the one year follow-up period. As the current study is not concerned 
with patients who involuntarily disengage from services, patients who move away, 
become incarcerated, or expire during the one year follow-up period have been excluded.  
Measures 
Patients enrolled in STEP are evaluated at baseline. Measures include basic 
demographics including age and address, current and past medications, medical history, 
the Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-
CV) (65), Positive and Negative Syndrome Scale (PANSS) (66), Columbia Suicide 
Severity Rating Scale (C-SSRS) (67), Global Assessment of Functioning Scale (GAF) 
24 
 
(6), Heinrich‟s Quality of Life (QOL) (68), Alcohol Use and Drug Use Scales 
(AUS/DUS) (69), Abnormal Involuntary Movement Scale (AIMS) (70), modified Social 
Functioning Scale (71), and a modified Service Use and Resources Form (SURF) (72). 
Patients receive follow-up measures every six months, for which they are compensated 
50 dollars. All evaluations are adminstered by a trained STEP affiliated clinician. These 
measures provided the demographic, educational, GAF, symptom profile, and forensic 
data employed in the current study. Service use was gathered from the modified SURF 
scale and medical chart review. These measures are repeated every six months if the 
patient is still in contact. 
Statistical Analysis 
Patients were grouped as being “engaged” or “disengaged” according to criteria 
described earlier in the methods section. We used Student‟s t-test to measure differences 
between these two populations on several continuous metrics, including age, duration of 
untreated psychosis (DUP), and baseline Global Assessment of Functioning (GAF).  
Differences in discrete variables, including level of family contact, forensic history, and 
baseline substance abuse were assessed by chi-square analysis. Family contact was 
converted to an indicator variable of 0, 1, or 2. Family status of “0” indicates that the 
patient has no contact with his or her family at the time of baseline assessment, “1” 
indicates the patient is in contact with his or her family but does not reside with them, and 
“2” indicates that the patient is currently residing with his or her family. In cases where a 
patient becomes disengaged, service utilization is calculated only for the months leading 
up to, but not including, the final month of engagement. We additionally assessed 
substance abuse at baseline and at 6 months, as prior literature has found a stronger 
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correlation between persistent substance abuse and disengagement than baseline 
substance abuse (28), though our analysis focuses on baseline substance abuse, since our 
focus is primarily in predicting risk of disengagement upon initiation of care 
All statistical analyses were performed using SPSS (IBM Corporation).   
Research Approval and Collaboration 
The STEP research protocol and all associated data analysis included in the current study 
was approved by the Human Investigation Committee at Yale University School of 
Medicine, New Haven, CT. All participants provided written informed consent 
authorizing use of clinical and demographic data for analyses. The current study was 
conceptualized by Matthew Kruse, Dr. Vivek Phutane, and Dr. Vinod Srihari. Mr. Kruse 
and Dr. Phutane gathered all clinical data and performed the statistical analysis. Mr. 
Kruse composed the initial and final versions of the current thesis, and Drs. Phutane and 
Srihari reviewed the first draft. 
Results 
Tables 1 and 2 display the investigated variables of the patient groups including age and 
gender. The mean age of patients in the current study was relatively young in both groups 
at approximately 20 years. The “engagement” group ages ranged from 17 to 30. The 
“disengagement” group ages ranged from 17 to 28. The patient population was 
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predominantly male (32 out of 39, or 82%). 
 
Table 1. Continuous variables and t-test results. 
All patients in the current study carried a clinical diagnosis of schizophrenia, 
schizophreniform disorder, schizoaffective disorder, or psychosis not otherwise specified. 
Disengagement Rate 
Among the 39 patients examined in the current study, 19 (49%) disengaged over the 
course of the first year. Among patients in the disengagement group, the most likely time 
for initial disengagement to occur was within the first three months of outpatient care, 
representing nine of 19 (36.8%) disengagement cases. Overall, the average time to initial 
disengagement was 3 months. Among the 19 patients who disengaged, 5 (26.3%) 
reinitiated clinical contact at some point before the end of the year follow-up. Figure 1 
demonstrates a relatively steep drop-off of engagement in the initial months of our 
follow-up period. 
Mean (S.D.) t Sig. (2-tailed)
Engagement Group 20.30 (7.94)
Disengagement Group 20.58 (2.59)
Engagement Group 21.50 (23.33)
Disengagement Group 27.95 (28.17)
Engagement Group 35.70 (6.46)
Disengagement Group 32.47 (10.40)
DUP (Weeks) 0.776 0.443
Baseline GAF -1.157 0.256




Figure 1. Patients with no disengagement periods in first year of treatment 
 
Predictive Variables 
Neither group demonstrated significant difference on any of the continuous variables 
examined, including age (t = 0.15; p = 0.88), clinic visits per month of engagement (t = 
1.75; p = 0.09), DUP (t = 0.78; p = 0.443) or baseline GAF (t = -1.16; p = 0.26) (Table 
1). Similarly, none of the discrete variables were significantly different between the 
engagement and disengagement groups, including gender (
2 
= 0.24; p = 0.62), contact 
with family (
2
 = 3.7; p = 0.16), forensic history (
2
 = 1.76; p = 0.18), or baseline 
substance abuse (
2
 = 1.25; p = 0.264) (Table 2). It was not clear whether these variables 
followed a normal distribution, but replication with non-parametric statistical tests did not 
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Table 2. Discrete variables and chi-square results. 
Although there were no significant differences in the two groups for any of the variables 
examined, some patterns emerged upon review of our data.  The mean DUP was slightly 
higher in the disengagement group (27.95;  = 28.17) than the engagement group (21.5; 
 = 21.5) though standard deviations were large, and statistical significance was not 
achieved. The mean baseline GAF was higher in the engagement group (35.7;  = 6.46) 
than the disengagement group (32.47;  = 10.4), but again not significantly so. In 
addition, the disengagement group seemed to have less contact with family. Of the five 
patients in the current sample who live alone with no contact with family, four (80%) 
were in the disengagement group. Of the six patients who live alone yet maintain contact 
with family, four (66%) were in the disengagement group. Among the remaining 28 
patients who live with family, only 11 (39%) of them disengaged from care. Despite a 
lack of statistical significance, all of these factors trended in the direction that we would 
have predicted from the literature (24, 28, 29, 32). 
 
Engaged Disengaged Chi-Square Sig. (2-sided)
Male 17 (43.6%) 15 (38.5%)
Female 3 (7.8%) 4 (10.3%)
Living Alone, No Contact 1 (2.6%) 4 (10.3%)
Living Alone with Contact 2 (5.1%) 4 (10.3%)
Living with Family 17 (43.6%) 11 (28.2%)
Forensic History 2 (5.1%) 5 (12.8%)
No Forensic History 18 (46.2%) 14 (35.9%)
Substance Abuse (baseline) 8 (20.5%) 11 (28.2%)








Specialized treatment for first episode psychosis is a growing trend internationally, with 
mixed yet promising data being published from clinics in locations including Australia 
(28), Canada (60), and the U.K. (47). Strengths of the current study include being among 
the first examinations of disengagement patterns associated with specialized early 
psychosis interventions in the United States. Our data and current definition of 
disengagement strives to maximize accuracy in identifying truly disengaged patients 
based on clinical attendance data, supported by prior disengagement analyses (25). 
Furthermore, our presentation of the data and unambiguous definitions of disengagement 
aims to facilitate future meta-analyses as more data is published on patient cohorts in the 
United States. 
Key Findings  
None of the variables examined in the current study were significantly different between 
the two groups examined in the current study. The lack of significance may have resulted 
from insufficient statistical power caused by a relatively small sample size.  
Although we did not uncover any variables that were significantly associated with 
disengagement in the first year of outpatient follow-up in FEP, the data on DUP, baseline 
GAF, connection with family, forensic history, and substance abuse trended in the same 
direction as would have been predicted in the literature. This consistency across all 
variables with previously published findings discussed in our introduction suggests our 
data trends may not be spurious findings, and may be an indicator of a type II statistical 




We failed to find any relationship between age and disengagement patterns in the current 
study. The mean ages of the engagement and disengagement groups were very similar 
(20.30 and 20.58 years, respectively). The standard deviation in the ages, conversely, 
were strikingly dissimilar between the engagement and disengagement groups (7.94 and 
2.59 years, respectively).  A post-hoc Levene‟s Test for Equality of Variances on the age 
variable was performed, revealing the variances to be significantly different (F = 5.28; p 
= 0.027). This data may suggest a unimodal disengagement risk over the age range of the 
current patient sample. In other words, those patients either at the lower or higher end of 
the current age distribution may be more prone to stay engaged in care, while those in the 
middle are at a relatively higher risk of dropout. Reasons for this distribution would be 
merely speculative at this point. Although literature reviews on schizophrenia have linked 
younger age to higher rates of disengagement, it might be reasonable to suggest that the 
risk of disengagement by younger patients may be overcome by the protective factor of 
living with parents (a high likelihood in the younger patients in the current study who are 
under 20 years old) (22). Older patients, meanwhile, may be more likely to remain 
engaged for the same reasons proposed by earlier studies, such as a correlation of later 
onset FEP with lower severity of illness or greater insight (30, 39). Our findings raise the 
possibility of a critical age of onset for psychosis that renders patients at a higher risk for 
disengagement, arising from the aggregate clinical and demographic factors that co-
segregate with that particular age range. On the other hand, if the predictive power of age 
is merely a result of co-segregation of other factors, a direct measurement of those other 




Only two patients in the engagement group have a forensic history, as compared to five in 
the disengagement group, a trend consistent with prior associations of forensic history 
with disengagement (31). It is still unclear why forensic history is associated with 
disengagement from healthcare services, though Lecomte et al. suggest that individuals 
who have a history of exposure to violence, abuse, or other forms of trauma are more 
likely to commit crimes themselves later in life. These same individuals, as a result of 
traumatic exposures, may develop impaired interpersonal dynamics, including an 
inherent mistrust of the status and authority of a healthcare provider. Hence, a history of 
trauma may be the confounding variable linking forensic history with service 
disengagement (31). 
Social Support 
A trend in family contact is consistent with the literature on disengagement patterns in 
psychiatric patient populations. Four patients in the disengagement group (21%) live 
alone with no contact with family. Meanwhile, only one patient in the engagement group 
(5%) lives alone with no contact with family. It is plausible that patients living alone with 
no contact with family may have difficulty establishing or maintaining relationships. 
These difficulties could extend beyond family or social circles, and form a barrier to 
establishing strong therapeutic relationships with healthcare providers. Alternatively, 
patients that have fewer social contacts may experience logistical impediments to care, 
including fewer social contacts to help remember appointments or greater difficulty 
arranging for transportation. The latter hypothesis introduces legitimate concerns about 
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why some patients may disengage from care. Patients who do not have access to 
transportation, or must financially support themselves and cannot take time off work, 
may stop showing up to appointments even if a strong therapeutic relationship is 
established. As one may suspect, an assessment of barriers to care in the United States 
revealed such difficulties to be common. Specifically, among individual with serious 
mental illness who recognized a need for psychiatric treatment, 52% reported prohibitive 
logistical barriers, such as being unsure where to seek help, or not having the time to 
attend appointments (31). Accordingly, the ease with which patients can attend 
appointments should be assessed by clinicians early in a course of treatment. The current 
study did not examine the reasons patients dropped out of treatment. Future studies with 
this and other data sets should explore the reasons care was discontinued, to assess any 
barriers to care that may be present and provide strategies to further improve engagement. 
Substance Abuse 
At baseline assessment, eight patients in the engaged population reported some element 
of substance abuse. By six months, this number had increased to 12 (data not shown). 
Prior literature has shown that persistent substance abuse (but not baseline substance 
abuse) is associated with greater risk of disengagement from treatment (24), and lower 
rates of positive symptom remission (40).  One explanation for this phenomenon is that 
patients who continue to abuse substances throughout their course of treatment may be 
less receptive to the advice of their healthcare providers, leading to poorer medication 
compliance and eventual discontinuation of clinical care. Alternatively, patients with 
persistent substance abuse may be self-medicating due to greater severity of illness or 
poor response to treatment. These patients may perceive formal medical care as being 
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less beneficial, which has been shown to increase the likelihood of disengagement (64). 
In the current study, the rate of substance abuse increased in the patients that remained 
engaged in treatment. It is unclear why this pattern was observed. On one hand, all of the 
patients in the current study are undergoing a first-episode of illness. It is possible that 
while adjusting to their illness, some patients might be predisposed to substance abuse as 
a form of self-medication, as speculated above. Indeed, a similar increase in substance 
abuse was noted in the disengagement group (11 patients at baseline, up to 14 at six 
months) (data not shown). The similar pattern between the engagement and 
disengagement groups might suggest that risks of substance abuse may be related to the 
inherent nature and symptoms of psychotic disorders rather than the external factors 
examined in the current study. Alternatively, as with the other comparisons in the current 
study, there is a chance that a limited sample size may lead to underpowered analysis, 
obscuring patterns that may otherwise be present. 
DUP  
There was a trend for higher DUP in the disengagement group in the current dataset. 
Although this difference was not significant, the data was in the direction we would have 
predicted from prior literature (32). As with many variables associated with 
disengagement from care, authors have speculated on why this relationship may exist, but 
the precise dynamics are still unclear. As noted before, some investigators speculate that 
schizophrenia and related disorders may reflect a neurodegenerative process which would 
be exacerbated by prolonged DUP and produce greater treatment and engagement 
challenges at baseline (5). Others hold that DUP may be confounded by associations with 
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other variables that independently predict delays in seeking treatment and poor 
engagement in services, such as poor social supports (38).  
Baseline GAF 
GAF is a subjective numeric scale used by mental health professionals to assess how well 
patients manage daily obligations and stressors, including social functioning, 
psychological coping, and vocational or educational performance (6). It is perhaps not 
surprising that prior studies have linked lower GAF scores to higher rates of 
disengagement, as difficulty or unwillingness in maintaining a relationship with mental 
health clinicians is precisely the type of poor functioning GAF is meant to measure. 
Similarly, by virtue of the metrics that it measures, GAF may correlate with illness 
severity. The alignment of GAF with both disengagement and illness severity may 
explain at least a portion of the correlation of disengagement with worse clinical 
outcomes. In agreement with previous studies on disengagement (28), our data trends 
suggest that lower GAF may be associated with higher disengagement rates in our patient 
population. As with other variables currently studied, a repeated study with a larger 
sample may yield a statistically significant relationship. 
Limitations 
Many of the studies on specialized psychiatric cohorts, including FEP patients receiving 
specialized early intervention, are limited by sample size. The current study is similarly 
limited by a sample of only 39 patients. In addition, much of the literature on service 
disengagement is plagued by the current disagreement on what constitutes 
disengagement, as illustrated earlier. Because our data was collected retrospectively, 
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some measures that would have made some of our analyses more meaningful could not 
be collected. Although methods for determining disengagement vary, most definitions 
discussed so far are based on the presence (or not) of clinical contact. Meanwhile, some 
argue that measuring disengagement should be much more nuanced. Some authors have 
noted that service disengagement is a product of the complex interactions of a patient‟s 
attitudes towards his or her illness, clinicians, and treatment (73). 
The Service Engagement Scale is a metric developed for objectively and thoroughly 
measuring engagement with services at community mental health centers. The scale 
measures engagement as a function of several metrics, including the ease with which 
patients can attend appointments, the perceived role of a patient in his or her care, a 
patient‟s perceived need or desire to seek help, and a patient‟s willingness to follow 
clinical advice and take medication. Evaluation of the scale has demonstrated that it is a 
highly reliable and valid measure of service engagement among patients with 
schizophrenia seeking treatment at a community mental health center (73). 
It is imperative that future studies examining disengagement begin adopting more 
consistent, reliable, and thorough measures of engagement and disengagement, allowing 
for more meaningful meta-analyses and data interpretation. In addition, adopting a more 
quantitative, nuanced measure of engagement may allow for more sensitive and specific 
stratification of patients according to engagement levels, improving the allocation of 
resources and outreach measures to those patients who will benefit most (73), or even 
boosting statistical power of future disengagement studies employing relatively small 
sample sizes. The current study was limited by not employing such a measure of 
disengagement, and while we used a working definition that we believed would 
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maximize our ability to identify patients who are truly disengaged from care, it‟s possible 
that the use of SES would have provided a superior measure. Additionally, our definition 
of disengagement allowed for a potential third group of patients: those who disengage 
from care but eventually return. It may be worthwhile in future studies with larger 
populations to either exclude these patients, or analyze them as a behaviorally distinct 
third group to uncover predictive variables with greater power. 
Finally, because we were primarily interested in the earlier, more critical periods for 
establishing clinical contact, we limited follow-up to one year. While likelihood of 
disengagement decreases as length of consistent clinical contact increases (24), we may 
have uncovered higher rates of disengagement had we examined service use over a 
longer period. 
Conclusions 
Specialized early intervention in psychosis is a growing trend in psychiatry, driven by the 
potential for superior clinical outcomes and more efficient allocation of economic 
resources. Much of the data on the benefit of early intervention is drawn from patient 
populations in Australia, Europe, and Canada. Even with a lack of statistical power, it 
appears that the factors that correlate with service disengagement in these countries may 
be similarly predictive in the United States. Specifically, patients with lower baseline 
GAF, longer DUP, forensic history, and less family contact may be more likely to 
discontinue treatment for psychotic illness in the first year of initial outpatient treatment.  
Early intervention clinics hoping to improve rates of service use do so via assertive 
treatment methods, including frequent contact with case workers, letter and telephone 
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reminders of appointments, and vocational assistance. By identifying factors at baseline 
that associate with service disengagement, early intervention clinics will be able to 
channel limited resources to those patients who are at higher risk of discontinuing care. 
Future studies should seek to analyze the predictive power of these and other factors with 
larger patient samples in the United States. More research should also assess which 
interventions improve service use among at-risk patients, allowing for even more 
efficient allocation of limited resources in these specialized clinics. Finally, future studies 
should compare the clinical and functional outcomes of patients who disengage from care 
those versus who do not. Although it is reasonable to suggest that a lack of regular 
contact with healthcare providers may lead to worse outcomes in patients with psychosis, 
additional data on the outcomes associated with disengagement is warranted, particularly 
in the unique healthcare infrastructure of the United States. Such associations would be 
beneficial in assessing the benefit of early intervention and other strategies to improve 
clinical engagement. 
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